Search companies

Live

CLEO DIAGNOSTICS LTD (ASX: COV)

Health care · News and insights

Price unavailable

Latest COV announcements

Cleo Sets Up US Lab Ahead Of Ovarian Cancer Test Validation

2026-11-12 · Health care

COV: $0.290 +1.75% · MC: $38M

Cleo Diagnostics has established the US laboratory infrastructure for clinical validation of its pre-surgical ovarian cancer test, with reproducibility studies underway and testing anticipated to begin within the next month. The program is expected to assess approximately 1,470 samples across three study groups and support a planned FDA 510(k) submission in the first half of 2027.

Updated 2026-11-12 09:13
Share
SourcesCLEO Advances Toward Clinical Validation
Comments

Cleo Diagnostics Advances Ovarian Cancer Test Validation, Screening Program Clears Early Benchmarks

2026-10-30 · Health care

COV: $0.295 -1.67% · MC: $38M

Cleo Diagnostics received its first production batch of test kits and began analytical validation, while engaging a U.S. laboratory for pivotal clinical testing; it continues to target an FDA submission in the first half of 2027. Its screening program’s initial retrospective study exceeded the company’s stated performance benchmarks, an early research result that still requires confirmation in larger, intended-use populations. Cash stood at approximately A$4 million at quarter-end.

Updated 2026-10-30 16:19
Share
SourcesQuarterly activities and cashflow report
Comments